Global Markets Direct’s, ‘Epidermolysis Bullosa - Pipeline Review, H2 2018’, provides an overview of the Epidermolysis Bullosa pipeline landscape.
The report provides comprehensive information on the therapeutics under development for Epidermolysis Bullosa, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Epidermolysis Bullosa and features dormant and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.
Scope
- The report provides a snapshot of the global therapeutic landscape of Epidermolysis Bullosa
- The report reviews pipeline therapeutics for Epidermolysis Bullosa by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Epidermolysis Bullosa therapeutics and enlists all their major and minor projects
- The report assesses Epidermolysis Bullosa therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Epidermolysis Bullosa
Reasons to buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Epidermolysis Bullosa
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Epidermolysis Bullosa pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Companies mentioned
Abeona Therapeutics Inc
Almirall SA
Amryt Pharma plc
Anterogen Co Ltd
Berg LLC
Celularity Inc
CSL Ltd
Fibrocell Science Inc
GlaxoSmithKline Plc
Immusoft Corp
InMed ...
Abeona Therapeutics Inc
Almirall SA
Amryt Pharma plc
Anterogen Co Ltd
Berg LLC
Celularity Inc
CSL Ltd
Fibrocell Science Inc
GlaxoSmithKline Plc
Immusoft Corp
InMed Pharmaceuticals Inc
Krystal Biotech Inc
MallInckrodt Plc
Mesoblast Ltd
Palvella Therapeutics LLC
ProQR Therapeutics NV
RegeneRx Biopharmaceuticals Inc
Shionogi & Co Ltd
Table of Contents
Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Epidermolysis Bullosa - Overview
Epidermolysis Bullosa - Therapeutics Development
Pipeline ...
Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Epidermolysis Bullosa - Overview
Epidermolysis Bullosa - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Epidermolysis Bullosa - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Epidermolysis Bullosa - Companies Involved in Therapeutics Development
Abeona Therapeutics Inc
Almirall SA
Amryt Pharma plc
Anterogen Co Ltd
Berg LLC
Celularity Inc
CSL Ltd
Fibrocell Science Inc
GlaxoSmithKline Plc
Immusoft Corp
InMed Pharmaceuticals Inc
Krystal Biotech Inc
MallInckrodt Plc
Mesoblast Ltd
Palvella Therapeutics LLC
ProQR Therapeutics NV
RegeneRx Biopharmaceuticals Inc
Shionogi & Co Ltd
Epidermolysis Bullosa - Drug Profiles
AC-203 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ADP-31415 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AGLE-103 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AP-103 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AZT-03 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
birch bark extract - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Cell Therapy for Dermatology and Immunology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Cell Therapy for Epidermolysis Bullosa - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CL-2020 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CSL-730 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Drugs for Dystrophic Epidermolysis Bullosa - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
EB-101 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
EB-201 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
FCX-007 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Gene Therapy for Epidermolysis Bullosa - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Gene Therapy to Activate COL7A1 for Epidermolysis Bullosa - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Gene Therapy to Activate COL7A1 for Epidermolysis Bullosa - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Gene Therapy to Activate Lysyl Hydroxylase-3 for Recessive Dystrophic Epidermolysis Bullosa - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Gene Therapy to Target COL7A1 for Recessive Dystrophic Epidermolysis Bullosa - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
HOLOGENE-17 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ICX-RHY - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
INM-750 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ISN-001 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
KB-103 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
KB-200 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PDA-002 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
QRX-313 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
QRX-323 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
QRX-333 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Recombinant Protein to Target COL7A1 for Epidermolysis Bullosa - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
remestemcel-L - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
RGN-137 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
S-005151 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
sirolimus - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Stem Cell Therapy for Diabetic Foot Ulcers, Epidermolysis Bullosa, Liver Diseases, Kidney Disease, Peripheral Artery Occlusive Disease and Skin Ulcers - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TXA-127 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ubidecarenone - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Epidermolysis Bullosa - Dormant Projects
Epidermolysis Bullosa - Discontinued Products
Epidermolysis Bullosa - Product Development Milestones
Featured News & Press Releases
Sep 25, 2018: Fibrocell awarded $1.4 million FDA orphan grant for FCX-007 for treatment of recessive dystrophic epidermolysis bullosa
Sep 10, 2018: Amryt receives IND approval from FDA for AP101 enabling the opening of US clinical trial sites
Aug 09, 2018: Castle Creek Pharmaceuticals receives FDA Fast Track Designation for Diacerein 1% ointment for treatment of Epidermolysis Bullosa Simplex
Aug 02, 2018: FDA grants Pediatric Rare Disease designation for AP101 for patients with Epidermolysis Bullosa
Jul 16, 2018: Krystal Biotech to Present Update on KB103 Program for Treatment of Dystrophic Epidermolysis Bullosa at debra Care Conference 2018
Jun 25, 2018: Castle Creek Pharmaceuticals Announces First Patient with Epidermolysis Bullosa Enrolled in Pharmacokinetics Study of Diacerein 1% Ointment
May 24, 2018: U.S. FDA Grants Fast Track Designation for Krystal Biotech’s KB103 for the Treatment of Dystrophic Epidermolysis Bullosa
May 23, 2018: BERG Announces FDA Orphan-Drug Designation of BPM 31510 for the Treatment of Patients with Epidermolysis Bullosa
May 21, 2018: Fibrocell Reports on Interim Results and Progress of Phase 1/2 Clinical Trial of FCX-007 Gene Therapy for Recessive Dystrophic Epidermolysis Bullosa
May 17, 2018: Abeona Reports Update from EB-101 Gene Therapy in Epidermolysis Bullosa at 21st Annual ASGCT Meeting
May 17, 2018: Celularity and New York Medical College Partner on a Breakthrough Study to Treat RDEB with Human Placental Derived Stem Cells
May 16, 2018: Castle Creek Pharmaceuticals Receives FDA Rare Pediatric Disease Designation for Diacerein 1% Ointment for Epidermolysis Bullosa
May 16, 2018: Fibrocell Announces Oral Presentation at 7th International Investigative Dermatology Meeting
May 10, 2018: Krystal Biotech Announces Dosing of First Patient in the Phase 1/2 trial of KB103, a First-in-Class Topical Gene Therapy for the Treatment of Dystrophic Epidermolysis Bullosa
May 09, 2018: Krystal Biotech Presents In Vivo KB103 Data at the International Investigative Dermatology Conference that Show Human COL7 Incorporating into Anchoring Fibrils with Proper Structural Orientation
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
List of Tables
Number of Products under Development for Epidermolysis Bullosa, H2 2018
Number of Products under Development by Companies, H2 2018
Number of Products ...
List of Tables
Number of Products under Development for Epidermolysis Bullosa, H2 2018
Number of Products under Development by Companies, H2 2018
Number of Products under Development by Companies, H2 2018 (Contd..1), H2 2018
Number of Products under Development by Universities/Institutes, H2 2018
Products under Development by Companies, H2 2018
Products under Development by Companies, H2 2018 (Contd..1), H2 2018
Products under Development by Companies, H2 2018 (Contd..2), H2 2018
Products under Development by Universities/Institutes, H2 2018
Number of Products by Stage and Target, H2 2018
Number of Products by Stage and Mechanism of Action, H2 2018
Number of Products by Stage and Route of Administration, H2 2018
Number of Products by Stage and Molecule Type, H2 2018
Epidermolysis Bullosa - Pipeline by Abeona Therapeutics Inc, H2 2018
Epidermolysis Bullosa - Pipeline by Almirall SA, H2 2018
Epidermolysis Bullosa - Pipeline by Amryt Pharma plc, H2 2018
Epidermolysis Bullosa - Pipeline by Anterogen Co Ltd, H2 2018
Epidermolysis Bullosa - Pipeline by Berg LLC, H2 2018
Epidermolysis Bullosa - Pipeline by Celularity Inc, H2 2018
Epidermolysis Bullosa - Pipeline by CSL Ltd, H2 2018
Epidermolysis Bullosa - Pipeline by Fibrocell Science Inc, H2 2018
Epidermolysis Bullosa - Pipeline by GlaxoSmithKline Plc, H2 2018
Epidermolysis Bullosa - Pipeline by Immusoft Corp, H2 2018
Epidermolysis Bullosa - Pipeline by InMed Pharmaceuticals Inc, H2 2018
Epidermolysis Bullosa - Pipeline by Krystal Biotech Inc, H2 2018
Epidermolysis Bullosa - Pipeline by MallInckrodt Plc, H2 2018
Epidermolysis Bullosa - Pipeline by Mesoblast Ltd, H2 2018
Epidermolysis Bullosa - Pipeline by Palvella Therapeutics LLC, H2 2018
Epidermolysis Bullosa - Pipeline by ProQR Therapeutics NV, H2 2018
Epidermolysis Bullosa - Pipeline by RegeneRx Biopharmaceuticals Inc, H2 2018
Epidermolysis Bullosa - Pipeline by Shionogi & Co Ltd, H2 2018
Epidermolysis Bullosa - Dormant Projects, H2 2018
Epidermolysis Bullosa - Discontinued Products, H2 2018
List of Figures
List of Figures
Number of Products under Development for Epidermolysis Bullosa, H2 2018
Number of Products under Development by Companies, H2 2018
Number of Products ...
List of Figures
Number of Products under Development for Epidermolysis Bullosa, H2 2018
Number of Products under Development by Companies, H2 2018
Number of Products under Development by Universities/Institutes, H2 2018
Number of Products by Top 10 Targets, H2 2018
Number of Products by Stage and Top 10 Targets, H2 2018
Number of Products by Top 10 Mechanism of Actions, H2 2018
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2018
Number of Products by Routes of Administration, H2 2018
Number of Products by Stage and Routes of Administration, H2 2018
Number of Products by Top 10 Molecule Types, H2 2018
Number of Products by Stage and Top 10 Molecule Types, H2 2018